drugset / Trial / NCT00471354

A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine

NCT00471354

Phase 4 Completed 228 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children treated with atomoxetine.

Timeline

Start
2007-04
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1.2 mg/kg Oral